- Houlahan, Kathleen E;
- Shiah, Yu-Jia;
- Gusev, Alexander;
- Yuan, Jiapei;
- Ahmed, Musaddeque;
- Shetty, Anamay;
- Ramanand, Susmita G;
- Yao, Cindy Q;
- Bell, Connor;
- O’Connor, Edward;
- Huang, Vincent;
- Fraser, Michael;
- Heisler, Lawrence E;
- Livingstone, Julie;
- Yamaguchi, Takafumi N;
- Rouette, Alexandre;
- Foucal, Adrien;
- Espiritu, Shadrielle Melijah G;
- Sinha, Ankit;
- Sam, Michelle;
- Timms, Lee;
- Johns, Jeremy;
- Wong, Ada;
- Murison, Alex;
- Orain, Michèle;
- Picard, Valérie;
- Hovington, Hélène;
- Bergeron, Alain;
- Lacombe, Louis;
- Lupien, Mathieu;
- Fradet, Yves;
- Têtu, Bernard;
- McPherson, John D;
- Pasaniuc, Bogdan;
- Kislinger, Thomas;
- Chua, Melvin LK;
- Pomerantz, Mark M;
- van der Kwast, Theodorus;
- Freedman, Matthew L;
- Mani, Ram S;
- He, Housheng H;
- Bristow, Robert G;
- Boutros, Paul C
Oncogenesis is driven by germline, environmental and stochastic factors. It is unknown how these interact to produce the molecular phenotypes of tumors. We therefore quantified the influence of germline polymorphisms on the somatic epigenome of 589 localized prostate tumors. Predisposition risk loci influence a tumor's epigenome, uncovering a mechanism for cancer susceptibility. We identified and validated 1,178 loci associated with altered methylation in tumoral but not nonmalignant tissue. These tumor methylation quantitative trait loci influence chromatin structure, as well as RNA and protein abundance. One prominent tumor methylation quantitative trait locus is associated with AKT1 expression and is predictive of relapse after definitive local therapy in both discovery and validation cohorts. These data reveal intricate crosstalk between the germ line and the epigenome of primary tumors, which may help identify germline biomarkers of aggressive disease to aid patient triage and optimize the use of more invasive or expensive diagnostic assays.